Drug intelligence / Profile preview

ASP-001

Development stage
Phase 4
Lead developer
Aspargo Laboratories
Modality
Small Molecules
Administration
Oral
01

Overview

ASP-001 is an oral spray formulation of sildenafil, the active ingredient in Viagra. Developed by Aspargo Laboratories using proprietary technology, it is designed for the treatment of erectile dysfunction (ED). The oral spray enables faster absorption—beginning within five minutes—compared to traditional tablet forms. This rapid onset may offer advantages for patients seeking more immediate effects. ASP-001 has received regulatory approval in several countries including Spain, Germany, the Netherlands, Ireland, Mexico, and the United Kingdom. It is marketed under brand names such as HEZKUE (Germany) and BANDOL (Spain). Aspargo Laboratories plans to seek FDA approval in the United States[1][2][3]. The mechanism of action is inhibition of type 5 cyclic nucleotide phosphodiesterase (PDE5), leading to increased blood flow in erectile tissue[1].

Brand names
HEZKUEBANDOL
Other names
sildenafil oral spray
02

Targets

PDE5A (Cyclic GMP-specific phosphodiesterase 5A)

Beyond the preview

Go deeper on ASP-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASP-001.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call